Articles tagged with Drug Therapy
Researchers from Zhejiang University School of Medicine have revealed key connections between clinical characteristics, neuroimaging, and treatment in obsessive-compulsive disorder (OCD). The study found that about 13-36% of patients show poor insight, linked to more severe symptoms and poorer treatment outcomes.
A new study from Sylvester Comprehensive Cancer Center suggests that prophylactic treatment can significantly reduce the rate of cytokine release syndrome (CRS) in multiple myeloma patients. This approach could eliminate hospital stays and broaden access to immunotherapy treatments for more cancer patients.
A large-scale German-wide randomized controlled trial found that high-dose therapy with glucocorticoids is not more effective than standard treatment for sudden hearing loss. However, it was associated with a higher risk of side effects. Several hundred thousand people worldwide suffer from sudden hearing loss each year.
GFH009 inhibits tumor growth and induces apoptosis in various HHM-derived cell lines. The compound's mechanism of action involves rapid 'on-off' inhibition of CDK9, which exerts a proapoptotic effect on cancer cells.
Researchers have developed a new method to generate cyclic peptides that can target diseases and be administered orally, overcoming challenges in protein binding. The approach enables high-throughput screening and has shown substantial bioavailability in rats, opening possibilities for treating various diseases.
The number of new dermatologic drug approvals by the FDA increased significantly between 2012 and 2022, with nearly half considered first in class or indication. This surge in approvals was deemed clinically useful or to have high added therapeutic benefit by health technology assessment organizations.
The use of 'trip-killers' to shorten psychedelic drug trips is a growing concern among doctors, with benzodiazepines and antipsychotics being the most frequently recommended options. However, warnings about their potential side effects are rarely included, highlighting a need for greater awareness.
A clinical trial found that an experimental drug, BI 690517, reduced albuminuria in 70% of patients when paired with a standard-care medication. The study also showed that the combination of the two drugs mitigated the risk of hyperkalemia.
Patients with lower socioeconomic status in their neighborhoods have a higher risk of nonadherence to guideline-directed medical therapy for heart failure. Neighborhood-level socioeconomic factors play a significant role in shaping healthcare outcomes.
A comprehensive review of targeted therapies for lupus nephritis discusses the challenges of current treatments and proposes strategies to overcome obstacles. Recent advancements in B-cell targeting and alternative approaches such as CAR-T cells are highlighted.
Researchers explore the properties of cytostatic persisters in cancer treatment, highlighting their therapeutic potential and challenges. The study suggests that targeting these persisters before resistance emerges can reduce cancer recurrence.
A novel synthesis method enables easy linkage of therapeutic oligonucleotides to peptide markers, streamlining the process and making it more accessible and cost-effective. This breakthrough has the potential to produce more effective and targeted RNA-based drugs.
Using metformin plus insulin to treat preexisting type 2 or gestational diabetes diagnosed early in pregnancy did not show a reduction in composite neonatal adverse outcomes. The study suggests that the effect of reducing large-for-gestational-age infant risk after adding metformin to insulin warrants further investigation.
A Northwestern University study found that nearly two-thirds of patients discontinue or change their medication within a year, highlighting the need for better understanding of barriers to treatment adherence. The high discontinuation rate for GLP-1 RAs may be due to gastrointestinal side effects.
A recent study published in JNCCN found that patients from underrepresented groups treated with first-line immunotherapy for advanced Non-Small Cell Lung Cancer (NSCLC) showed similar survival outcomes as their White counterparts. The study analyzed data from 248 patients and highlighted the need for more diverse patient representation...
A landmark study found that 92% of patients with severe asthma can safely reduce inhaled steroid dose and more than 60% can stop all use, minimizing side effects like osteoporosis, diabetes, and cataracts. The SHAMAL study used biologic therapy benralizumab to control severe asthma without steroids.
Researchers leverage AI to analyze healthcare data and identify new targets for effective therapies and accelerate drug development in aging research. AI can tailor cancer treatment more precisely to individual patients' unique aging profiles, optimizing treatment outcomes and minimizing risks.
Researchers found that a person-centered approach, trusting relationship, and proper training are crucial for effective peer support. Trained peer support can help plug gaps in medication advice and improve patient adherence to treatment.
Researchers at the University of Turku found that bexmarilimab therapy alters macrophage behavior to promote anti-tumor immune defense. The therapy was well-tolerated and stabilized disease progression in patients with advanced-stage cancer, inducing tumor-associated macrophage and lymphocyte activation.
Researchers found that a breakthrough infection builds upon existing memory B cell pool and introduces random mutations that prepare antibodies for new variants. Broad neutralizing antibodies can neutralize all tested Omicron variants.
Researchers found that BCMA-positive extracellular vesicles (EVs) in plasma levels correlated with myeloma patient responses to belantamab-mafodotin therapy. High EV levels preceded FLC progression and were associated with mafodotin-induced eryptosis.
A team of Kyoto University researchers found that macrophages produce granulomas through a hyperactive metabolic pathway called the pentose phosphate pathway. Inhibition of this pathway showed therapeutic efficacy in reducing granuloma formation in vitro and in mouse tissue models.
Imetelstat, a telomerase inhibitor, successfully treated anaemia in MDS patients for up to one year, reducing the need for red blood cell transfusions. The drug offers a novel mechanism of action for patients with lower-risk MDS who do not respond to standard treatment.
A team of researchers at UMass Amherst has discovered a crucial role played by the enzyme UGGT in protein folding. The study reveals how UGGT 'tags' misfolded proteins with specific sugars, enabling chaperones to identify and correct errors.
Researchers have discovered a new approach to targeting transcription factors in prostate cancer by exploiting the formation of protein droplets. This process can be used to inhibit androgen receptor activity, which is essential for the growth and survival of cancer cells.
A study by the University of the Basque Country uses game theory to establish that tumours with less cellular heterogeneity are more aggressive. The work suggests a fresh theoretical approach for new therapeutic strategies, focusing on preserving high intratumour heterogeneity.
Researchers have identified macrocyclic compounds as a potential solution for targeting proteins critical to tumorigenesis, blocking nearly 80% of cancer's signature characteristic events. Additionally, these small compact molecules can effectively overcome drug resistance by binding to mutant proteins and inhibiting their activities.
Researchers found that 1,8-cineole inhibits inflammatory pathways in the gut, while ginsenoside Rk2 alleviates liver inflammation and restores intestinal barrier function. Another compound, specnuezhenide, modifies gut microbiota and has potential to inhibit colorectal tumor growth.
Researchers developed a flexible new platform that solves part of the daunting delivery problem in cell and gene therapies. The workhorses behind this platform are extracellular vesicles, which bind to target cells and effectively transfer drugs inside.
Researchers at NTNU are developing a new therapy for rare hereditary diseases like DOOR syndrome using mini-brains grown in the lab. The treatment involves injecting a virus with a healthy OXR1 gene to produce the missing protein, which may help stop or reverse the disease.
A study of 278,000 individuals in Sweden found that longer cumulative duration of ADHD medication use was associated with an increased risk of hypertension and arterial disease. Clinicians should regularly monitor cardiovascular signs and symptoms during long-term treatment.
A Phase II clinical trial has shown a clear clinical benefit of combining Dabrafenib and Trametinib in treating BRAF mutated low-grade paediatric gliomas. The combination therapy improved overall response rate by over four-fold and increased median progression-free survival.
A new study found that vosoritide treatment increases height, facial volume, and foramen magnum size in young children with achondroplasia, reducing sudden infant death syndrome, sleep apnea, and surgery needs. Vosoritide may improve quality of life and potentially save lives by addressing the root cause of the condition.
Researchers have summarized recent advances in enzyme-activated near-infrared fluorescent probes for non-invasive visualization of enzyme dynamics and disease status. These probes offer high specificity, sensitivity, and biocompatibility, making them valuable assets in biomedical research and healthcare.
Researchers at Nagoya University identified the link between iron and blindness caused by ocular toxoplasmosis, a parasite affecting one-third of the world's population. Controlling iron levels has shown promise as a potential cure.
Researchers at Hokkaido University found that cancer stem cells cause macrophages to age, suppressing their antitumor activity. Supplementing mice with nicotinamide mononucleotide restored macrophage function and prevented tumor growth.
A randomized clinical trial of 2,858 patients with new-onset and worsening chronic heart failure shows that torsemide and furosemide have no significant difference in clinical or patient-reported outcomes at 12 months. Torsemide is associated with better outcomes for patients with de novo heart failure.
The Max Foundation has started treating three patients with advanced breast cancer, including a CDK4/6 inhibitor therapy, in Mozambique. This marks the first time this treatment is available in low-income countries and aims to improve outcomes for women living with advanced breast cancer.
Lepodisiran, a short interfering RNA, targets hepatic synthesis of apolipoprotein(a), reducing serum lipoprotein(a) concentrations. Phase 1 study results support further investigation of lepodisiran's efficacy in treating elevated lipoprotein(a) levels.
A survey found that 42% of primary care physicians are unaware of biologic treatments for asthma, and 82% do not get necessary labs to determine treatment options. This lack of knowledge can lead to delayed referrals to asthma specialists and reduced effectiveness in managing symptoms.
The C-Path Neuroscience Annual Workshop brought together stakeholders to chart a transformative course for neurology research and drug development, focusing on chronic progressive diseases such as Alzheimer's and Parkinson's. Key highlights included recommendations for innovative therapies and tools to address complex disorders.
Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.
Maintenance immunosuppressive drugs linked to increased COVID-19 hospitalization risk in solid organ transplant patients. Clinicians treating transplant recipients should consider these findings for epidemic-related decisions.
A study published in Oncotarget reveals that HER2 mutant alleles play a crucial role in determining treatment response to neratinib and poziotinib. Researchers found that individual HER2 mutant alleles have distinct effects on therapeutic efficacy, suggesting new targets for breast cancer therapy.
Researchers found that changing treatment can lead to significant improvement in mobility and quality of life for patients with advanced Parkinson's disease. A nationwide registry is planned to develop scientifically sound guidelines for combination therapies.
A new study by RCSI University of Medicine and Health Sciences found that boosting levels of a deficient protein improves survival rates for people with severe alpha-1 antitrypsin deficiency. The research, which tracked health data from over 600 patients, showed a clear survival benefit from augmentation therapy.
A small clinical trial led by the University of Houston demonstrates Riluzole's effectiveness in improving functionality in people with acute spinal cord injuries. The study used an SCI-specific biomarker to show how Riluzole reduces neuron cell damage and improves motor abilities.
A new classification system for heart attacks based on heart muscle damage is released, offering a more differentiated definition and improving understanding of acute atherothrombotic MI. This system has the potential to stratify risk more accurately and lay the groundwork for development of injury-stage-specific therapies.
Scientists at Nagoya University developed a new gastric acid inhibitor with a binding affinity nearly 10 times higher than existing drugs. The AI-driven approach led to the creation of compound DQ-18, which exhibits stronger binding to the gastric proton pump.
A groundbreaking clinical trial launched by the U.S. Army aims to find new treatments for post-traumatic stress disorder (PTSD) in military personnel and veterans. The trial will test multiple drug candidates and examine biological indicators to determine potential treatments.
The Cumming Global Centre for Pandemic Therapeutics is offering global grants of up to $200,000 per annum for three years to develop novel therapeutics for pathogens of pandemic potential. Researchers are invited to submit expressions of interest for Round Two of the Foundation Grants program.
A new study published in Science Advances suggests that a decades-old anti-anxiety drug can improve the effectiveness of chemo-radiotherapy towards glioblastoma, the most common and lethal brain cancer. The researchers found that the drug trifluoperazine can re-sensitize tumor cells to both therapies, leading to improved patient survival.
Stanford researchers have discovered a pathway to break down problematic proteins, which can be harnessed to develop new treatments for diseases such as Alzheimer's and cancer. The findings also offer insights into lysosome storage disorders, rare conditions that affect babies and children.
Scientists have discovered a new small molecule called Feeblin that inhibits the interaction of SLC15A4 with TASL, a key player in pro-inflammatory signalling pathways. This finding offers promising new treatment options for patients with autoimmune diseases like systemic lupus.
Tongxinluo significantly improved 30-day and 1-year clinical outcomes in STEMI patients, according to a randomized clinical trial. Further research is needed to understand its mechanism of action.
A secondary analysis of the SWOG S0931 trial found that patients with very-high risk clear-cell renal cell carcinoma who received adjuvant everolimus after surgery had a statistically significant improvement in recurrence-free survival. The results suggest that everolimus may be beneficial for this high-risk patient population, but als...
Researchers found that tumour cells escape immunotherapy by losing or changing BCMA and GPRC5D targets on their surface. This understanding has led to the suggestion of periodically profiling myeloma cells throughout a patient's treatment course to adapt treatment strategies.
A new hormone replacement therapy, Pulsatility, has shown promising results in improving symptoms and quality of life for patients with adrenal insufficiency conditions. The treatment, which delivers hydrocortisone in a pulsatile pattern, decreased fatigue by 10% and improved mood and energy levels by 30%.
Researchers discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy. Cancer cells respond to radiation by rewiring metabolic signaling pathways using lactic acid instead of glucose.
Researchers are testing a single target to weaken tumors and strengthen immune cells in pediatric brain tumor patients. The goal is to improve the effectiveness of CAR-T therapy, which has shown promise but also leads to exhaustion of immune cells.